ArticleCurrent therapeutic research, clinical and experimental2026
Prevalence and correlates of antinuclear antibodies in a Japanese community sample: a cross-sectional study.
Article in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antinuclear antibodies (ANA) are among the most commonly used tests in autoimmune disease but are frequently positive in healthy individuals, with uncertain significance. Reported prevalence ranges from under 6% to over 45% across populations, and its determinants in healthy individuals are poorly defined. Objective: We examined ANA prevalence and its demographic and lifestyle correlates in a community sample in Japan. Methods: Serum samples were obtained from 1,017 community residents in a single prefecture in Japan. Age and sex were recorded for all participants; smoking status and allergic history were available for a subset (n = 467). ANA were measured by indirect immunofluorescence on HEp-2 cells; a 1:40 titer defined positivity. Associations were assessed using chi-square tests, logistic regression with linear and quadratic age terms, and multivariable logistic regression adjusting sequentially for age, sex, smoking, and allergic history. Results: Among 1,017 participants (542 women and 475 men), overall ANA positivity was 18.3% (186/1,017). Positivity was significantly higher in women than in men (21.8% vs. 14.3%) and showed a U-shaped age pattern in women. ANA positivity was not associated with allergic history. Exploratory subgroup analysis showed higher positivity in current or former smokers than never-smokers among men. After adjustment for age, female sex was independently associated with ANA positivity (OR 1.72, 95% CI 1.24-2.40). In the lifestyle subset, female sex was the only independently associated factor after adjustment for age, smoking status, and allergic history. Conclusions: These data provide a population-specific baseline for ANA positivity in a Japanese community sample and confirm that prevalence is higher in women and varies with age. Because ANA is frequently measured and may precede autoimmune disease, longitudinal studies are needed to clarify whether incidental positivity in healthy individuals carries prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.